GCH1 and Parkinson disease: This is derived both from imaging evidence of striatal dopaminergic denervation in GCH1 pathogenic variant carriers with a clinical diagnosis of definite Parkinson’s disease (in DOPA-responsive dystonia pedigrees) and from exome sequencing data that show a significant association between GCH1 coding variants and an increased risk for the disease.